Cargando…
Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
Somatostatin analogues can suppress the secretion of some gastrointestinal hormones and growth factors involved in the growth regulation of gastrointestinal cancers and can inhibit the growth of experimental pancreatic tumours. Therefore, in a phase II study 34 patients with metastatic pancreatic (n...
Autores principales: | Klijn, J. G., Hoff, A. M., Planting, A. S., Verweij, J., Kok, T., Lamberts, S. W., Portengen, H., Foekens, J. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971491/ https://www.ncbi.nlm.nih.gov/pubmed/1977468 |
Ejemplares similares
-
Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin.
por: Nelson, J., et al.
Publicado: (1989) -
Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
por: Bontenbal, M., et al.
Publicado: (1998) -
Sandostatin therapy in patients with chronic sarcoidosis
por: Timmermans, Wilhelmina M.C., et al.
Publicado: (2017) -
Antiproliferative effects of somatostatin analogs in endocrine tumours
por: Zatelli, Maria Chiara
Publicado: (2009) -
Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)